Sanjib Bhakta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2953087/publications.pdf

Version: 2024-02-01

90 papers	2,922 citations	126907 33 h-index	197818 49 g-index
95 all docs	95 docs citations	95 times ranked	3613 citing authors

#	Article	IF	Citations
1	Role of AmpC-Inducing Genes in Modulating Other Serine Beta-Lactamases in Escherichia coli. Antibiotics, 2022, 11, 67.	3.7	2
2	Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition. Journal of Medicinal Chemistry, 2022, 65, 234-256.	6.4	11
3	Immunobiology of tubercle bacilli and prospects of immunomodulatory drugs to tackle tuberculosis (TB) and other non-tubercular mycobacterial infections. Immunobiology, 2022, 227, 152224.	1.9	1
4	The Phytochemistry and Pharmacology of Tulbaghia, Allium, Crinum and Cyrtanthus: â€˜Talentedâ€™ Taxa from the Amaryllidaceae. Molecules, 2022, 27, 4475.	3.8	2
5	The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review. Antibiotics, 2021, 10, 91.	3.7	10
6	Characterization of the MurT/GatD complex in Mycobacterium tuberculosis towards validating a novel anti-tubercular drug target. JAC-Antimicrobial Resistance, 2021, 3, dlab028.	2.1	7
7	Weighted Gene Co-Expression Network Analysis Identifies Key Modules and Hub Genes Associated with Mycobacterial Infection of Human Macrophages. Antibiotics, 2021, 10, 97.	3.7	8
8	New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis. Pharmaceuticals, 2021, 14, 361.	3.8	14
9	Investigating Ghanaian Allium Species for Anti-Infective and Resistance-Reversal Natural Product Leads to Mitigate Multidrug-Resistance in Tuberculosis. Antibiotics, 2021, 10, 902.	3.7	3
10	The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis. Journal of Medicinal Chemistry, 2021, 64, 71-100.	6.4	32
11	Pathogenesis and Host Immune Response in Leprosy. Advances in Experimental Medicine and Biology, 2021, 1313, 155-177.	1.6	5
12	Vaccination Strategies Against Mycobacterium tuberculosis: BCG and Beyond. Advances in Experimental Medicine and Biology, 2021, 1313, 217-240.	1.6	1
13	Exploration of 5â€(5â€nitrothiophenâ€2â€yl)â€4,5â€dihydroâ€1Hâ€pyrazoles as selective, multitargeted antimycobacterial agents. Chemical Biology and Drug Design, 2020, 95, 192-199.	3.2	10
14	Improving the Potency of N-Aryl-2,5-dimethylpyrroles against Multidrug-Resistant and Intracellular Mycobacteria. ACS Medicinal Chemistry Letters, 2020, 11, 638-644.	2.8	9
15	Antimicrobial and Efflux Pump Inhibitory Activity of Carvotacetones from Sphaeranthus africanus Against Mycobacteria. Antibiotics, 2020, 9, 390.	3.7	13
16	Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis. Journal of Antimicrobial Chemotherapy, 2020, 75, 3194-3201.	3.0	16
17	Bioactive Compounds from the Bornean Endemic Plant Goniothalamus longistipetes. Antibiotics, 2020, 9, 913.	3.7	1
18	Synthesis and Biological Evaluation of a Novel C8-Pyrrolobenzodiazepine (PBD) Adenosine Conjugate. A Study on the Role of the PBD Ring in the Biological Activity of PBD-Conjugates. Molecules, 2020, 25, 1243.	3.8	5

#	Article	IF	Citations
19	3-(5-Nitrofuran-2-yl)prop-2-en-1-one Derivatives, with Potent Antituberculosis Activity, Inhibit A Novel Therapeutic Target, Arylamine N-acetyltransferase, in Mycobacteria. Antibiotics, 2020, 9, 368.	3.7	7
20	Flavonoids as Novel Efflux Pump Inhibitors and Antimicrobials Against Both Environmental and Pathogenic Intracellular Mycobacterial Species. Molecules, 2020, 25, 734.	3.8	38
21	Natural and trained innate immunity against Mycobacterium tuberculosis. Immunobiology, 2020, 225, 151951.	1.9	51
22	Chalcones, stilbenes and ketones have anti-infective properties via inhibition of bacterial drug-efflux and consequential synergism with antimicrobial agents. Access Microbiology, 2020, 2, acmi000105.	0.5	8
23	Human Antimicrobial RNases Inhibit Intracellular Bacterial Growth and Induce Autophagy in Mycobacteria-Infected Macrophages. Frontiers in Immunology, 2019, 10, 1500.	4.8	20
24	Synthesis and mycobacterial evaluation of 5â€substitutedâ€6â€acetylâ€2â€aminoâ€7â€methylâ€5,8â€dihydropyridoâ€[2,3â€d]pyrimidinâ€4(3H)â€one derivatives. Archiv Der Pharmazie, 2019, 352, 1900068.	1.7	3
25	Integrated Targetâ€Based and Phenotypic Screening Approaches for the Identification of Antiâ€Tubercular Agents That Bind to the Mycobacterial Adenylating Enzyme MbtA. ChemMedChem, 2019, 14, 1735-1741.	3.2	9
26	Cell wall peptidoglycan inMycobacterium tuberculosis: An Achillesâ€™ heel for the TB-causing pathogen. FEMS Microbiology Reviews, 2019, 43, 548-575.	8.6	131
27	Prospects of Pre-clinical [6.6.0] Bicyclic Nitrogen Heterocycles in the Treatment of Tuberculosis. , 2019, , 147-165.		0
28	Analogues of Disulfides from Allium stipitatum Demonstrate Potent Anti-tubercular Activities through Drug Efflux Pump and Biofilm Inhibition. Scientific Reports, 2018, 8, 1150.	3.3	23
29	Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents. European Journal of Medicinal Chemistry, 2018, 160, 49-60.	5.5	65
30	Arylamine N-Acetyltransferase in Mycobacteria. , 2018, , 303-324.		0
31	Investigation of the mycobacterial enzyme HsaD as a potential novel target for antiâ€tubercular agents using a fragmentâ€based drug design approach. British Journal of Pharmacology, 2017, 174, 2209-2224.	5.4	19
32	Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis. European Journal of Medicinal Chemistry, 2017, 127, 147-158.	5.5	25
33	Nano-Formulation of Ethambutol with Multifunctional Graphene Oxide and Magnetic Nanoparticles Retains Its Anti-Tubercular Activity with Prospects of Improving Chemotherapeutic Efficacy. Molecules, 2017, 22, 1697.	3.8	20
34	Novel Anti-Tuberculosis Nanodelivery Formulation of Ethambutol with Graphene Oxide. Molecules, 2017, 22, 1560.	3.8	25
35	Host Antimicrobial Peptides: The Promise of New Treatment Strategies against Tuberculosis. Frontiers in Immunology, 2017, 8, 1499.	4.8	77
36	Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. British Medical Bulletin, 2016, 118, 138-148.	6.9	63

#	Article	IF	Citations
37	DNA sequence-selective C8-linked pyrrolobenzodiazepineâ€“heterocyclic polyamide conjugates show anti-tubercular-specific activities. Journal of Antibiotics, 2016, 69, 843-849.	2.0	12
38	UV-curable gels as topical nail medicines:In vivo residence, anti-fungal efficacy and influence of gel components on their properties. International Journal of Pharmaceutics, 2016, 514, 244-254.	5.2	3
39	HTâ€SPOTi: A Rapid Drug Susceptibility Test (DST) to Evaluate Antibiotic Resistance Profiles and Novel Chemicals for Antiâ€Infective Drug Discovery. Current Protocols in Microbiology, 2016, 40, 17.8.1-17.8.12.	6.5	39
40	Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-Nâ€²-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercular Agents Effective against Multidrug-Resistant Mycobacteria. Journal of Medicinal Chemistry, 2016, 59, 2780-2793.	6.4	51
41	Repositioning of DHFR Inhibitors. Current Topics in Medicinal Chemistry, 2016, 16, 2125-2143.	2.1	12
42	Development of a rapid, reliable and quantitative method â€" â€œSPOTiâ€•for testing antifungal efficacy. Journal of Microbiological Methods, 2015, 117, 36-40.	1.6	11
43	The draft genome of Mycobacterium aurum, a potential model organism for investigating drugs against Mycobacterium tuberculosis and Mycobacterium leprae. International Journal of Mycobacteriology, 2015, 4, 207-216.	0.6	19
44	Tetrahydroisoquinolines affect the whole-cell phenotype of Mycobacterium tuberculosis by inhibiting the ATP-dependent MurE ligase. Journal of Antimicrobial Chemotherapy, 2015, 70, 1691-1703.	3.0	24
45	Synthesis, anti-mycobacterial activity and DNA sequence-selectivity of a library of biaryl-motifs containing polyamides. Bioorganic and Medicinal Chemistry, 2015, 23, 3705-3711.	3.0	10
46	Repurposingâ€"a ray of hope in tackling extensively drug resistance in tuberculosis. International Journal of Infectious Diseases, 2015, 32, 50-55.	3.3	64
47	Structure of the stationary phase survival protein YuiC from B.subtilis. BMC Structural Biology, 2015, 15, 12.	2.3	7
48	Antagonistic effects of indoloquinazoline alkaloids on antimycobacterial activity of evocarpine. Journal of Applied Microbiology, 2015, 118, 864-872.	3.1	26
49	Lasso Peptides and Murein Peptide Ligase Inhibitors as Novel Anti-Mycobacterial Agents. , 2015, , .		0
50	Characterisation of a putative AraC transcriptional regulator from Mycobacterium smegmatis. Tuberculosis, 2014, 94, 664-671.	1.9	12
51	Exploration of Piperidinols as Potential Antitubercular Agents. Molecules, 2014, 19, 16274-16290.	3.8	16
52	ProTides of N-(3-(5-(2â€²-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents. Bioorganic and Medicinal Chemistry, 2014, 22, 2816-2824.	3.0	27
53	2-Hydroxy-substituted cinnamic acids and acetanilides are selective growth inhibitors of Mycobacterium tuberculosis. MedChemComm, 2014, 5, 47-50.	3.4	43
54	Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents. Journal of Ethnopharmacology, 2014, 155, 796-800.	4.1	54

#	Article	IF	Citations
55	A new plant-derived antibacterial is an inhibitor of efflux pumps in Staphylococcus aureus. International Journal of Antimicrobial Agents, 2013, 42, 513-518.	2.5	62
56	Antimycobacterials from Lovage Root (Ligusticum officinale Koch). Phytotherapy Research, 2013, 27, 993-998.	5.8	25
57	An Integration of Interdisciplinary Translational Research in Anti-TB Drug Discovery: Out of the University Research Laboratories to Combat Mycobacterium tuberculosis. Molecular Biology (Los) Tj ETQq1 1 0.784314 rgBT /Overloc	4.3	1
58	Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open, 2013, 3, e002672.	1.9	74
59	Characterisation of ATP-Dependent Mur Ligases Involved in the Biogenesis of Cell Wall Peptidoglycan in Mycobacterium tuberculosis. PLoS ONE, 2013, 8, e60143.	2.5	71
60	An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2012, 67, 1380-1391.	3.0	68
61	Synthesis and Antibacterial Evaluation of a New Series of N-Alkyl-2-alkynyl/(E)-alkenyl-4-(1H)-quinolones. Molecules, 2012, 17, 8217-8240.	3.8	17
62	Versatile Routes to Marine Sponge Metabolites through Benzylidene Rhodanines. Organic Letters, 2012, 14, 6310-6313.	4.6	18
63	The Properties of Solutions of Isoniazid in Water and Dimethylsulfoxide. Journal of Solution Chemistry, 2012, 41, 1462-1476.	1.2	11
64	Synthesis and Biological Evaluation of Purpurealidin E-Derived Marine Sponge Metabolites: Aplysamine-2, Aplyzanzine A, and Suberedamines A and B. Journal of Natural Products, 2012, 75, 1090-1101.	3.0	18
65	Antioxidant, Antitubercular and Cytotoxic Activities of Piper imperiale. Molecules, 2012, 17, 4142-4157.	3.8	23
66	An antibacterial from Hypericum acmosepalum inhibits ATP-dependent MurE ligase from Mycobacterium tuberculosis. International Journal of Antimicrobial Agents, 2012, 39, 124-129.	2.5	52
67	Piperidinols That Show Anti-Tubercular Activity as Inhibitors of Arylamine N-Acetyltransferase: An Essential Enzyme for Mycobacterial Survival Inside Macrophages. PLoS ONE, 2012, 7, e52790.	2.5	27
68	Antimycobacterials from natural sources: ancient times, antibiotic era and novel scaffolds. Frontiers in Bioscience - Landmark, 2012, 17, 1861.	3.0	35
69	Mycobacterium tuberculosis: Immune evasion, latency and reactivation. Immunobiology, 2012, 217, 363-374.	1.9	151
70	Characterization of an oxidoreductase from the arylamine Nâ€acetyltransferase operon in Mycobacteriumâ€ƒsmegmatis. FEBS Journal, 2011, 278, 4824-4832.	4.7	4
71	Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics. Journal of Antimicrobial Chemotherapy, 2011, 66, 1766-1772.	3.0	37
72	Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars. Protein and Cell, 2010, 1, 82-95.	11.0	45

#	Article	IF	Citations
73	Essential residues for the enzyme activity of ATP-dependent MurE ligase from Mycobacterium tuberculosis. Protein and Cell, 2010, 1, 1011-1022.	11.0	32
74	ATP-dependent MurE ligase in Mycobacterium tuberculosis: Biochemical and structural characterisation. Tuberculosis, 2010, 90, 16-24.	1.9	49
75	Rapid Methods for Testing Inhibitors of Mycobacterial Growth. Methods in Molecular Biology, 2010, 642, 193-201.	0.9	35
76	Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2010, 65, 2101-2107.	3.0	77
77	Fast-growing, non-infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituberculosis drug screening. Journal of Antimicrobial Chemotherapy, 2009, 64, 774-781.	3.0	35
78	Bioactive Pyridine-N-oxide Disulfides from Allium stipitatum. Journal of Natural Products, 2009, 72, 360-365.	3.0	103
79	Arylamine N-Acetyltransferases in Mycobacteria. Current Drug Metabolism, 2008, 9, 510-519.	1.2	38
80	Synthesis of putative chain terminators of mycobacterial arabinan biosynthesis. Organic and Biomolecular Chemistry, 2007, 5, 2257.	2.8	24
81	Inhibition of mycobacterial arylamine N-acetyltransferase contributes to anti-mycobacterial activity of Warburgia salutaris. Bioorganic and Medicinal Chemistry, 2007, 15, 3579-3586.	3.0	48
82	Characterization of the putative operon containing arylamine N-acetyltransferase (nat) in Mycobacterium bovis BCG. Molecular Microbiology, 2006, 59, 181-192.	2.5	43
83	Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochemical Journal, 2005, 385, 605-612.	3.7	72
84	Arylamine N-Acetyltransferase Is Required for Synthesis of Mycolic Acids and Complex Lipids in Mycobacterium bovis BCG and Represents a Novel Drug Target. Journal of Experimental Medicine, 2004, 199, 1191-1199.	8.5	93
85	Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function. Biochemical Society Transactions, 2003, 31, 615-619.	3.4	46
86	Interaction between FtsZ and FtsW of Mycobacterium tuberculosis. Journal of Biological Chemistry, 2002, 277, 24983-24987.	3.4	81
87	Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis. Biochemical Journal, 2002, 361, 635.	3.7	20
88	Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochemical Journal, 2002, 367, 279-285.	3.7	132
89	Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1â^— and its soluble derivative from Mycobacterium tuberculosis. Biochemical Journal, 2002, 361, 635-639.	3.7	23
90	Characterization of derivatives of the high-molecular-mass penicillin-binding protein (PBP) 1 of Mycobacterium leprae. Biochemical Journal, 2000, 350, 75-80.	3.7	15